Criticism as Brian King Named Director of FDA Center for Tobacco Products

News
May.20.2022
Criticism as Brian King Named Director of FDA Center for Tobacco Products

Brian King, currently a higher-up at the Centers for Disease Control and Prevention (CDC) in Atlanta, will become the new director of the Food and Drug Administration’s Center for Tobacco Products (CTP), the FDA announced on May 20.

 

An epidemiologist, King has spent more than a decade at the CDC, most recently as the deputy director for research translation at the Office on Smoking and Health (OSH). He will assume his new role on July 3, 2022. His predecessor as permanent director, Mitch Zeller, retired in the spring after a contentious career; the CTP has since been headed by Michele Mital on an interim basis.

 

The news comes at a time when CTP still has to sort through many of the premarket tobacco product applications (PMTAs) from the largest vape manufacturers, and as the office has been under recent fire for poor public health communication about the relative risks of e-cigarettes and safer nicotine alternatives. The reaction among consumer advocates was mixed at best: Some expressed cautious optimism that an epidemiologist might understand the issues better than a lawyer like Zeller, while others feared this might be just a status-quo move—or worse.

 

Many observers have pointed to King’s botching, in his CDC role, of the lung illnesses—misleadingly dubbed “e-cigarette or vaping use-associated lung injury,” or EVALI—that cropped up in the summer of 2019. Three years later, the CDC has still failed to be explicit that the cases were only tied to vaping illicitly manufactured, adulterated THC cartridges—and not nicotine, as the agency originally implied.

 

“Brian King’s long history of obfuscation around the issue of tobacco harm reduction is hard to ignore.”

 

Criticism has also been levied at King’s past comments on e-cigarettes. He’s accused of having overemphasized the harms of vaping products among youth at the expense of their harm reduction role for adult smokers, and of fear-mongering—through claims that e-cigarettes could be modified to contain “heroin, methamphetamines, powdered cocaine, and bath salts.”

 

“While there is always value in optimism, Brian King’s long history of obfuscation around the issue of tobacco harm reduction is hard to ignore,” Greg Conley, the president of the American Vaping Association (AVA), told Filter. “In his role at the Office on Smoking and Health, King has ignored or downplayed CDC’s own surveys showing several million adult ex-smokers using vaping as a total alternative for smoking, while leaping at opportunities to make absurd claims about the impacts of youth vaping. We are hopeful the FDA’s hiring of an ideologue to act as a supposedly neutral regulator will lead to renewed interest in this issue by members of Congress.”

 

“Brian King is among the worst choices for CTP that exists,” an industry insider, who requested anonymity so as not to affect his company’s PMTAs, told Filter. “He has no understanding of tobacco harm reduction or the continuum of risk, and has demonstrated a fundamental misunderstanding of what an e-cigarette even is. I expect his reign to be plagued by litigation [and that he] never accomplishes any of his stated goals for the regulation of the industry.”

 

In a letter circulated to FDA staff, Robert Califf, the agency’s commissioner, lauded King on his expertise, writing that “he has an extensive and nuanced understanding of, and appreciation for the 2009 Family Smoking and Prevention Act, detailed knowledge of premarket review pathways, premarket tobacco product applications, substantial equivalence, and modified risk tobacco products, as well as experience in the interagency scientific review of regulatory documents related to tobacco product standards, testing and reporting of ingredients, and health information.”

 

King, for his part, is anxious to get started.

 

“There’s critical work to be done to further prevent people from starting to use tobacco products, encourage tobacco users to quit and reduce the harm caused by tobacco use,” King said in a press statement. “During my time at CDC, I’ve had the great privilege to work with the staff at the FDA’s Center for Tobacco Products on a number of important tobacco issues, and I’m excited to lead CTP to advance these efforts.”

 

Source:filtermag

PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives